As the ASX200 experiences fluctuations, with sectors like Utilities and Real Estate showing strength while Discretionary faces challenges, investors are keenly observing growth opportunities in the market. In such an environment, companies with significant insider ownership can be particularly appealing as they often indicate confidence from those closest to the business's operations and future prospects.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Alfabs Australia (ASX:AAL) | 10.8% | 40.9% |
| Gratifii (ASX:GTI) | 13.1% | 114.0% |
| Fenix Resources (ASX:FEX) | 21.1% | 45.1% |
| Acrux (ASX:ACR) | 15.6% | 106.9% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| AVA Risk Group (ASX:AVA) | 16% | 108.2% |
| Titomic (ASX:TTT) | 11.2% | 77.2% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| Change Financial (ASX:CCA) | 26.8% | 106.4% |
| Findi (ASX:FND) | 35.6% | 133.7% |
Below we spotlight a couple of our favorites from our exclusive screener.
Aurelia Metals (ASX:AMI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Aurelia Metals Limited is involved in the exploration and production of mineral properties in Australia, with a market cap of A$414.43 million.
Operations: The company's revenue is derived from its operations at the Hera Mine (A$5.98 million), Peak Mine (A$245.13 million), and Dargues Mine (A$73.90 million).
Insider Ownership: 23.2%
Aurelia Metals demonstrates potential as a growth company with high insider ownership, driven by forecasted earnings growth of 32.3% annually, surpassing the Australian market average. Despite a low projected return on equity of 11.4%, the company has transitioned to profitability, reporting A$17.95 million net income for H1 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly, indicating strategic resource management amidst fluctuating commodity performance.
- Dive into the specifics of Aurelia Metals here with our thorough growth forecast report.
- The analysis detailed in our Aurelia Metals valuation report hints at an inflated share price compared to its estimated value.
Clarity Pharmaceuticals (ASX:CU6)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company involved in the research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$903 million.
Operations: The company's revenue is derived from its radiopharmaceutical development segment, totaling A$10.78 million.
Insider Ownership: 17.8%
Clarity Pharmaceuticals shows promise with high insider ownership, driven by its innovative radiopharmaceuticals pipeline. Recent FDA Fast Track Designations for Cu-SAR-bisPSMA highlight its potential in treating prostate cancer, supported by positive trial results. Revenue rose to A$10.94 million for H1 2024, though net losses widened to A$23.58 million due to ongoing R&D investments. Despite past shareholder dilution, Clarity's revenue is forecasted to grow significantly faster than the market at 66.2% annually.
- Take a closer look at Clarity Pharmaceuticals' potential here in our earnings growth report.
- Our valuation report here indicates Clarity Pharmaceuticals may be overvalued.
PolyNovo (ASX:PNV)
Simply Wall St Growth Rating: ★★★★★☆
Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across the United States, Australia, New Zealand, and internationally with a market cap of A$880.82 million.
Operations: The company's revenue primarily comes from the development, manufacturing, and commercialization of the NovoSorb technology, amounting to A$115.58 million.
Insider Ownership: 10.2%
PolyNovo demonstrates growth potential with its earnings forecasted to increase significantly at 40.5% annually, surpassing the Australian market's average. Recent half-year results show revenue of A$59.89 million, up from A$48.77 million year-over-year, and net income rising to A$3.34 million. Despite a high level of non-cash earnings and trading below estimated fair value, insider activity shows more shares bought than sold recently but not in substantial volumes, indicating cautious optimism among insiders.
- Navigate through the intricacies of PolyNovo with our comprehensive analyst estimates report here.
- Upon reviewing our latest valuation report, PolyNovo's share price might be too optimistic.
Key Takeaways
- Explore the 90 names from our Fast Growing ASX Companies With High Insider Ownership screener here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Clarity Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com